litlas
Log inCreate account

Daniel W. Visscher

Active 1985–2022

86
Papers
23,020
Citations
72
h-index
86
i10-index

Citations

Citations per year for Daniel W. Visscher1974: 1 citations1987: 2 citations1988: 1 citations1989: 4 citations1991: 8 citations1992: 3 citations1993: 6 citations1994: 8 citations1995: 16 citations1996: 31 citations1997: 33 citations1998: 39 citations1999: 45 citations2000: 39 citations2001: 56 citations2002: 49 citations2003: 43 citations2004: 58 citations2005: 54 citations2006: 129 citations2007: 192 citations2008: 216 citations2009: 212 citations2010: 201 citations2011: 268 citations2012: 207 citations2013: 217 citations2014: 260 citations2015: 258 citations2016: 193 citations2017: 195 citations2018: 184 citations2019: 604 citations2020: 665 citations2021: 504 citations2022: 385 citations2023: 234 citations2024: 345 citations2025: 135 citations2026: 5 citations1975–1986: no citations, so these years are not shown1990: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,699 citing papers, 30.8% of this breakdownChina: 709 citing papers, 8.1% of this breakdownUnited Kingdom: 543 citing papers, 6.2% of this breakdownItaly: 402 citing papers, 4.6% of this breakdownGermany: 382 citing papers, 4.4% of this breakdownCanada: 359 citing papers, 4.1% of this breakdownFrance: 290 citing papers, 3.3% of this breakdownJapan: 255 citing papers, 2.9% of this breakdownSouth Korea: 243 citing papers, 2.8% of this breakdownSpain: 230 citing papers, 2.6% of this breakdownAustralia: 229 citing papers, 2.6% of this breakdownNetherlands: 222 citing papers, 2.5% of this breakdown
0%30.8%Other 25.1%

Institutions

Fields

  • Medicine55.3%
  • Biochemistry, Genetics and Molecular Biology35%
  • Computer Science2.5%
  • Immunology and Microbiology2.2%
  • Pharmacology, Toxicology and Pharmaceutics1.7%
  • Engineering1%
  • Other2.3%

Topics

  • Breast Cancer Treatment Studies9.9%
  • HER2/EGFR in Cancer Research7.9%
  • Breast Lesions and Carcinomas4.4%
  • Monoclonal and Polyclonal Antibodies Research2.4%
  • Advanced Breast Cancer Therapies2.4%
  • Cancer Cells and Metastasis2.3%
  • Other70.7%

Coauthors

All papers

Open in search
  1. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

    Authors: M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett, D. Craig Allred, Karen L. Hagerty, Sunil Badve, Patrick L. Fitzgibbons, Glenn Francis, Neil S. Goldstein, Malcolm Hayes, David G. Hicks, Susan C. Lester, Richard R. Love, Pamela B. Mangu, Lisa M. McShane, Keith Miller, C. Kent Osborne, Soonmyung Paik, Jane Perlmutter, Anthony Rhodes, Hironobu Sasano, Jared N. Schwartz, Fred C.G.J. Sweep, Sheila E. Taube, Emina Torlakovic, Paul N. Valenstein, Giuseppe Viale, Daniel W. Visscher, Thomas M. Wheeler, Roger Williams, James L. Wittliff, Antonio C. Wolff - Archives of Pathology & Laboratory Medicine 2010 cited by 4,267

  2. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

    Authors: Edward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela Klein, James N. Ingle, Norman Wolmark - New England Journal of Medicine 2005 cited by 5,353

  3. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)

    Authors: M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett, D. Craig Allred, Karen L. Hagerty, Sunil Badve, Patrick L. Fitzgibbons, Glenn Francis, Neil S. Goldstein, Malcolm Hayes, David G. Hicks, Susan C. Lester, Richard R. Love, Pamela B. Mangu, Lisa M. McShane, Keith Miller, C. Kent Osborne, Soonmyung Paik, Jane Perlmutter, Anthony Rhodes, Hironobu Sasano, Jared N. Schwartz, Fred C.G.J. Sweep, Sheila E. Taube, Emina Torlakovic, Paul N. Valenstein, Giuseppe Viale, Daniel W. Visscher, Thomas M. Wheeler, Roger Williams, James L. Wittliff, Antonio C. Wolff - Archives of Pathology & Laboratory Medicine 2010 cited by 1,048

  4. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine

    Authors: Jia Yu, Bo Qin, Ann M. Moyer, Somaira Nowsheen, Tongzheng Liu, Sisi Qin, Yongxian Zhuang, Duan Liu, W. Lu, Krishna R. Kalari, Daniel W. Visscher, John A. Copland, Sarah A. McLaughlin, Alvaro Moreno‐Aspitia, Donald W. Northfelt, Richard J. Gray, Zhenkun Lou, Vera J. Suman, Richard Weinshilboum, Judy C. Boughey, Matthew P. Goetz, Liewei Wang - Journal of Clinical Investigation 2018 cited by 210

  5. Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug Resistance

    Authors: Sanjib Bhattacharyya, Sounik Saha, Karuna Giri, Ian R. Lanza, K.S. Nair, Nicholas B. Jennings, Cristian Rodriguez‐Aguayo, Gabriel Lopez‐Berestein, Eati Basal, Amy L. Weaver, Daniel W. Visscher, William A. Cliby, Anil K. Sood, Resham Bhattacharya, Priyabrata Mukherjee - PLoS ONE 2013 cited by 252

  6. Benign Breast Disease and the Risk of Breast Cancer

    Authors: Lynn C. Hartmann, Thomas A. Sellers, Marlene H. Frost, Wilma L. Lingle, Amy C. Degnim, Karthik Ghosh, Robert A. Vierkant, Shaun D. Maloney, V. Shane Pankratz, David W. Hillman, Vera J. Suman, Jo Johnson, Cassann Blake, Thea D. Tlsty, Celine M. Vachon, L. Joseph Melton, Daniel W. Visscher - New England Journal of Medicine 2005 cited by 942

  7. The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer

    Authors: Claudia C. Preston, Matthew J. Maurer, Ann L. Oberg, Daniel W. Visscher, Kimberly R. Kalli, Lynn C. Hartmann, Ellen L. Goode, Keith L. Knutson - PLoS ONE 2013 cited by 210

  8. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients

    Authors: Nadine Norton, Bahaaeldin Youssef, David W. Hillman, Aziza Nassar, Xochiquetzal J. Geiger, Brian M. Necela, Heshan Liu, Kathryn J. Ruddy, Mei‐Yin C. Polley, James N. Ingle, Fergus J. Couch, Edith A. Perez, Minetta C. Liu, Jodi M. Carter, Roberto A. Leon‐Ferre, Judy C. Boughey, Elizabeth B. Somers, Krishna R. Kalari, Daniel W. Visscher, Matthew P. Goetz, Keith L. Knutson - npj Breast Cancer 2020 cited by 72

  9. Age-Related Lobular Involution and Risk of Breast Cancer

    Authors: Tia R. Milanese, Lynn C. Hartmann, Thomas A. Sellers, Marlene H. Frost, Robert A. Vierkant, Shaun D. Maloney, V. Shane Pankratz, Amy C. Degnim, Celine M. Vachon, Carol Reynolds, Romayne Thompson, L. Joseph Melton, Ellen L. Goode, Daniel W. Visscher - JNCI Journal of the National Cancer Institute 2006 cited by 248

  10. Immune cell quantitation in normal breast tissue lobules with and without lobulitis

    Authors: Amy C. Degnim, Rushin D. Brahmbhatt, Derek C. Radisky, Tanya L. Hoskin, Melody Stallings‐Mann, Mark Laudenschlager, Aaron S. Mansfield, Marlene H. Frost, Linda Murphy, Keith L. Knutson, Daniel W. Visscher - Breast Cancer Research and Treatment 2014 cited by 100

  11. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

    Authors: Matthew P. Goetz, James M. Rae, Vera J. Suman, Stephanie L. Safgren, Matthew M. Ames, Daniel W. Visscher, Carol Reynolds, Fergus J. Couch, Wilma L. Lingle, David A. Flockhart, Zeruesenay Desta, Edith A. Perez, James N. Ingle - Journal of Clinical Oncology 2005 cited by 786

  12. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

    Authors: Peter C. Brooks, Staffan Strömblad, Richard Klemke, Daniel W. Visscher, F. H. Sarkar, David A. Cheresh - Journal of Clinical Investigation 1995 cited by 831

  13. Mammographic density and risk of breast cancer by age and tumor characteristics

    Authors: Kimberly A. Bertrand, Rulla M. Tamimi, Christopher G. Scott, Matthew R. Jensen, V. Shane Pankratz, Daniel W. Visscher, Aaron D. Norman, Fergus J. Couch, John Shepherd, Bo Fan, Yunn‐Yi Chen, Lin Ma, Andrew H. Beck, Steven R. Cummings, Karla Kerlikowske, Celine M. Vachon - Breast Cancer Research 2013 cited by 187

  14. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer

    Authors: Roberto A. Leon‐Ferre, Mei‐Yin C. Polley, Heshan Liu, Judith A Gilbert, Victoria Cafourek, David W. Hillman, Ahmed Elkhanany, Margaret Akinhanmi, Jenna Lilyquist, Abigail Thomas, Vivian Negron, Judy C. Boughey, Minetta C. Liu, James N. Ingle, Krishna R. Kalari, Fergus J. Couch, Daniel W. Visscher, Matthew P. Goetz - Breast Cancer Research and Treatment 2017 cited by 106

  15. Centrally Necrotizing Carcinomas of the Breast

    Authors: Rafael E. Jiménez, Tracy Wallis, Daniel W. Visscher - The American Journal of Surgical Pathology 2001 cited by 86

  16. Pathology of breast cancer in the last half century

    Authors: Malvika Solanki, Daniel W. Visscher - Human Pathology 2019 cited by 60

  17. HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

    Authors: Edith A. Perez, Vera J. Suman, Nancy E. Davidson, Silvana Martino, Peter A. Kaufman, Wilma L. Lingle, Patrick J. Flynn, James N. Ingle, Daniel W. Visscher, Robert B. Jenkins - Journal of Clinical Oncology 2006 cited by 443

  18. Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study

    Authors: Lynn C. Hartmann, Derek C. Radisky, Marlene H. Frost, Richard J. Santen, Robert A. Vierkant, Lorelle L. Benetti, Yaman Tarabishy, Karthik Ghosh, Daniel W. Visscher, Amy C. Degnim - Cancer Prevention Research 2014 cited by 231

  19. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

    Authors: Zahraa Al‐Hilli, Grace M. Choong, Michael Keeney, Daniel W. Visscher, James N. Ingle, Matthew P. Goetz, James W. Jakub - Breast Cancer Research and Treatment 2019 cited by 87

  20. Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer

    Authors: Matthew P. Goetz, Krishna R. Kalari, Vera J. Suman, Ann M. Moyer, Jia Yu, Daniel W. Visscher, Travis Dockter, Peter T. Vedell, Jason P. Sinnwell, Xiaojia Tang, Kevin J. Thompson, Poulami Barman, Douglas W. Mahoney, Erin E. Carlson, Steven N. Hart, Ping Yin, Bo Qin, Sara J. Felten, Sarah A. McLaughlin, Alvaro Moreno‐Aspitia, John A. Copland, Donald W. Northfelt, Richard J. Gray, Katie N. Hunt, Amy Lynn Conners, Hugues Sicotte, Jeanette E. Eckel‐Passow, Jean‐Pierre Kocher, James N. Ingle, Marissa S. Ellingson, Michelle McDonough, Eric D. Wieben, Richard M. Weinshilboum, Liewei Wang, Judy C. Boughey - JNCI Journal of the National Cancer Institute 2016 cited by 83

  21. Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients

    Authors: Maeve Mullooly, Hannah Yang, Roni T. Falk, Sarah J. Nyante, Renata Cora, Ruth M. Pfeiffer, Derek C. Radisky, Daniel W. Visscher, Lynn C. Hartmann, Jodi M. Carter, Amy C. Degnim, Frank Z. Stanczyk, Jonine D. Figueroa, Montserrat García‐Closas, Jolanta Lissowska, Melissa A. Troester, Stephen M. Hewitt, Louise A. Brinton, Mark E. Sherman, Gretchen L. Gierach - Breast Cancer Research 2017 cited by 76

  22. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies

    Authors: Jiayin Shen, Yingwen Hu, Karson S. Putt, Sunil Singhal, Haiyong Han, Daniel W. Visscher, Linda M. Murphy, Philip S. Low - Oncotarget 2017 cited by 76

  23. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

    Authors: Rachel M. Hurley, Andrea E. Wahner Hendrickson, Daniel W. Visscher, Peter Ansell, Maria I. Harrell, Jill M. Wagner, Vivian Negron, Krista M. Goergen, Matthew J. Maurer, Ann L. Oberg, X. Wei Meng, Karen S. Flatten, Maja J.A. de Jonge, Carla D. Van Herpen, Jourik A. Gietema, Rutger H.T. Koornstra, Agnes Jager, Martha W. den Hollander, Matthew W. Dudley, Stacie Peacock Shepherd, Elizabeth M. Swisher, Scott H. Kaufmann - Gynecologic Oncology 2019 cited by 74

  24. Genes associated with bowel metastases in ovarian cancer

    Authors: Andrea Mariani, Chen Wang, Ann L. Oberg, Shaun M. Riska, Michelle Torres, Joseph Kumka, Francesco Multinu, Gunisha Sagar, Debarshi Roy, Deok‐Beom Jung, Qing Zhang, Tommaso Grassi, Daniel W. Visscher, Vatsal P. Patel, Ling Jin, Julie Staub, William A. Cliby, Saravut J. Weroha, Kimberly R. Kalli, Lynn C. Hartmann, Scott H. Kaufmann, Ellen L. Goode, Viji Shridhar - Gynecologic Oncology 2019 cited by 62